Valuation : Exscientia plc

Market Cap 500M 676M 583M 552M 937M 64.57B 944M 6.55B 2.52B 32.85B 2.54B 2.48B 104B P/E 2022
-4.55x
P/E 2023 -4.28x
Enterprise Value 156M 211M 182M 172M 292M 20.12B 294M 2.04B 785M 10.23B 790M 773M 32.34B EV / Sales 2022
1.9x
EV / Sales 2023 14.2x
Free-Float
36.87%
Yield 2022 *
-
Yield 2023 -
3 years 3.8
Extreme 3.8
7.91
5 years 3.8
Extreme 3.8
30.38
10 years 3.8
Extreme 3.8
30.38
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 2024-06-05
Chief Tech/Sci/R&D Officer - 2022-04-30
Chief Tech/Sci/R&D Officer - 2024-04-30
Director TitleAgeSince
Director/Board Member 63 2017-09-27
Director/Board Member 43 2020-04-30
Chairman 61 2024-02-11
Change 5-day change 1-year change 3-year change Capi.($)
+3.20%-.--% - - 633M
Average +3.20%
Weighted average by Cap. +3.20%

Financials

2022 2023
Net sales 27.22M 36.81M 31.74M 30.07M 51.04M 3.52B 51.42M 357M 137M 1.79B 138M 135M 5.65B 20.08M 27.15M 23.41M 22.18M 37.64M 2.59B 37.93M 263M 101M 1.32B 102M 99.71M 4.17B
Net income -119M -161M -138M -131M -223M -15.34B -224M -1.56B -598M -7.8B -603M -590M -24.66B -146M -197M -170M -161M -274M -18.86B -276M -1.91B -736M -9.59B -741M -725M -30.32B
Net Debt -492M -665M -574M -543M -922M -63.55B -929M -6.45B -2.48B -32.33B -2.5B -2.44B -102B -344M -465M -401M -380M -645M -44.46B -650M -4.51B -1.73B -22.62B -1.75B -1.71B -71.48B
Logo Exscientia plc
Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
Employees
483
  1. Stock Market
  2. Stocks
  3. EXAI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!